BioMimetix ’s Post

🎗️ 📢 Prostate Cancer Awareness Month📢🎗️ September 1st marked the start of Prostate Cancer Awareness Month. This month serves as a crucial reminder of the importance of understanding Prostate Cancer. Becoming aware of the risks and symptoms of Prostate Cancer could lead to earlier diagnosis and more effective treatments. Throughout this month, Verity Pharmaceuticals will be sharing valuable insights, facts, and resources on Prostate Cancer. Stay tuned to our page so you don’t miss a post! #MensHealth #ProstateCancerAwareness #PCAM #ProstateCancer

Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar on 26 June at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment technology, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT technology, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Are you studying the mechanisms of different cancer-immune pathways? Request a free copy of the wallchart: Rational Combination of Cancer Therapies with PD1 Axis Blockade. #cancer #immunotherapy #research #naturereviews

Dive into the world of antibody-drug conjugates with Sino Biological, Inc.! Discover how these innovative therapeutics target cancer cells with precision, sparing healthy tissues from harm. Read their latest article to learn more about the latest advancements in cancer treatment! >>> https://hubs.ly/Q02qHYlG0

Check out our latest article with BioTechniques!

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn ✅ What new treatment has recently been approved ✅ Exploring the results of the CAPItello-291 trial ✅ How these results led to the treatment being FDA-approved ✅ Who this treatment will work for ✅ Explanation of statistics used in this trial ✅ What tests a patient needs to determine if this treatment will work for them ✅ Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn 👇 ✅What new treatment has recently been approved ✅Exploring the results of the CAPItello-291 trial ✅How these results led to the treatment being FDA-approved ✅Who this treatment will work for ✅Explanation of statistics used in this trial ✅What tests a patient needs to determine if this treatment will work for them ✅Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

KRAS Inhibitors is EOS Intelligence's focus for June and we will be publishing new content every week. The KRAS oncogene has long been a challenging target in cancer therapy, but recent breakthroughs are transforming the competitive landscape. As the race to develop effective KRAS inhibitors intensifies, understanding this dynamic market is crucial for stakeholders. Here's a closer look at the innovations, challenges, and key players shaping the KRAS competitive landscape. The race to develop effective KRAS inhibitors represents a pivotal moment in cancer treatment. Companies that navigate this competitive landscape successfully will unlock new potentials in oncology, bringing hope to patients and advancing the frontiers of medicine. If you wish to discuss, reach out! #KRASInhibitors #CancerTherapy #OncologyInnovation #PrecisionMedicine #PharmaLeadership

👩⚕️ One of the biggest challenges in oncology is resistance. 1 in 2 people will be diagnosed with cancer in their lifetime, and over 90 % of cancer deaths are caused by drug resistance, one of the biggest unmet medical needs in the field of cancer. 👨⚕️   🎯 At Heidelberg Pharma AG the patient is the focus of all our efforts! Our amanitin-based ADC pipeline is designed to overcome resistance. 🎯 📌 Learn more about our patient-focused approach by watching our R&D webinar: https://lnkd.in/eVJygzyn   #ADCs #ATAC #CancerResearch

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn 👇 ✅What new treatment has recently been approved ✅Exploring the results of the CAPItello-291 trial ✅How these results led to the treatment being FDA-approved ✅Who this treatment will work for ✅Explanation of statistics used in this trial ✅What tests a patient needs to determine if this treatment will work for them ✅Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine